In a victory for Centocor Ortho Biotech, a district court has upheld the company’s $1.7 billion jury award for Abbott Laboratories’ infringement on its Humira patent. The U.S. District Court for the Eastern District of Texas found that Abbott did not prove that the patent is unenforceable or invalid, according to court records posted online last week. The lawsuit, filed in 2007, alleges that Abbott willfully infringed the Centocor’s patent by manufacturing Humira (adalimumab), a tumor necrosis factor (TNF) alpha blocker.
Drug Industry Daily